Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248495 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00248495 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 38 participants.
The verdict
NCT00248495, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them before and after surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving pemetrexed disodium and cisplatin before and after surgery works in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
Interventions
- DRUG cisplatin
- PROCEDURE conventional surgery
- PROCEDURE adjuvant therapy
- DRUG pemetrexed disodium
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2005-06-08 |
| Est. Completion | 2017-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00248495
The ClinicalTrials.gov registry entry for NCT00248495 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00248495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00248495 about?
NCT00248495 is a clinical study titled "Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them before and after surgery may ...
What is the current status of trial NCT00248495?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2005-06-08. Estimated completion is 2017-04-05.
What interventions are being tested in trial NCT00248495?
The interventions under investigation include: cisplatin (DRUG), conventional surgery (PROCEDURE), adjuvant therapy (PROCEDURE), pemetrexed disodium (DRUG), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00248495?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.